+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Canine Atopic Dermatitis - Global Strategic Business Report

  • PDF Icon

    Report

  • 93 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5303352
The global market for Canine Atopic Dermatitis was estimated at US$1.5 Billion in 2023 and is projected to reach US$2.5 Billion by 2030, growing at a CAGR of 8.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Canine Atopic Dermatitis Market - Key Trends & Drivers Summarized

Why Is Canine Atopic Dermatitis Gaining Attention in Veterinary Healthcare?

Canine atopic dermatitis (CAD) is one of the most common skin disorders affecting dogs, characterized by chronic inflammation and itching caused by environmental allergens such as pollen, dust mites, and molds. The condition is gaining significant attention in veterinary healthcare due to its increasing prevalence and its impact on dogs' quality of life. Canine atopic dermatitis often leads to persistent itching, scratching, and skin infections, which can cause significant discomfort and require long-term management. Veterinary experts estimate that 10% to 15% of dogs globally suffer from some form of atopic dermatitis, with certain breeds like Golden Retrievers, Bulldogs, and German Shepherds being particularly prone to the condition. Pet owners are becoming more aware of canine skin health, and there is a growing demand for effective treatments that address both the symptoms and the underlying causes of CAD. The veterinary healthcare industry has responded by developing a range of therapies, including corticosteroids, antihistamines, immune-modulating drugs, and specialized diets designed to reduce allergic reactions. As pet ownership rises, particularly in developed countries where pets are considered part of the family, more resources are being devoted to the diagnosis, treatment, and management of chronic conditions like CAD.

How Are Innovations in Diagnosis and Treatment Improving Canine Atopic Dermatitis Care?

Advancements in diagnostic tools and treatments are revolutionizing the management of canine atopic dermatitis. Veterinarians are now using more precise diagnostic methods, such as intradermal skin testing and allergen-specific immunotherapy (ASIT), to identify the specific allergens triggering a dog's symptoms. These diagnostic techniques allow for more targeted and personalized treatments, which can significantly improve outcomes. In particular, ASIT involves desensitizing dogs to the allergens they are allergic to, reducing their allergic reactions over time. This form of treatment is particularly beneficial for dogs that do not respond well to conventional therapies or have severe, recurring symptoms. On the treatment front, there have been notable advancements in the development of biologic therapies and immunomodulators. Cytopoint, for instance, is a monoclonal antibody that targets interleukin-31 (IL-31), a key protein involved in the itch signal, and has gained popularity for its ability to provide long-lasting relief from itching with fewer side effects compared to traditional corticosteroids. Similarly, Apoquel, an immune-modulating drug, has been widely adopted for its effectiveness in reducing inflammation and itchiness in dogs with atopic dermatitis. These treatments, which offer more targeted approaches with fewer side effects, represent significant progress in managing a condition that often requires lifelong therapy.

How Are Changing Consumer Behaviors Shaping the Canine Atopic Dermatitis Market?

As pet ownership trends evolve, consumer behaviors are increasingly influencing the canine atopic dermatitis market. Pet owners today are more invested in their pets` health and well-being, often seeking premium healthcare solutions and proactive treatments. This growing trend of 'humanization' of pets is driving demand for advanced and innovative therapies that not only alleviate symptoms but also improve the overall quality of life for pets. As a result, veterinary healthcare providers are witnessing a rising demand for personalized treatments, allergen-free diets, and even alternative therapies such as acupuncture and herbal treatments to manage canine atopic dermatitis.

Another key factor shaping the market is the increased use of telemedicine and digital health platforms in veterinary care. Pet owners are turning to online platforms to consult with veterinary dermatologists and access information on how to better manage chronic conditions like CAD. This shift toward digital healthcare services is making it easier for pet owners to receive timely advice and access specialized care that may not be readily available locally. Moreover, the demand for natural and organic pet products is influencing the development of hypoallergenic pet foods and topical treatments, which cater to owners seeking gentler, non-pharmaceutical approaches to managing their dogs' skin conditions.

Growth in the Canine Atopic Dermatitis Market Is Driven by Several Factors

Growth in the canine atopic dermatitis market is driven by several factors, including advancements in veterinary healthcare, the rising awareness among pet owners, and the increasing demand for innovative treatments. Technological progress in diagnostics, particularly in identifying specific allergens through skin testing and serum-based tests, has enabled veterinarians to offer more targeted and effective treatments for dogs with atopic dermatitis. The introduction of biologic therapies, like monoclonal antibodies and immune modulators, has provided pet owners with more options for long-term management of the condition, reducing the need for steroids and other drugs that can have severe side effects when used over extended periods. Another key growth driver is the rising number of pet owners who are more invested in ensuring their pets receive high-quality healthcare. This demographic shift, particularly in developed regions, has led to increased spending on veterinary services and medications, including those related to skin conditions like CAD. The growing interest in hypoallergenic diets and allergen-free pet products is also boosting the market for dietary interventions and topical treatments aimed at controlling flare-ups. Additionally, the integration of telemedicine in veterinary care is making it easier for pet owners to manage chronic conditions like CAD, with online consultations offering guidance on treatment plans and symptom management. These factors, along with the increasing focus on pet wellness and preventative care, are expected to continue driving the expansion of the canine atopic dermatitis market.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Glucocorticoids segment, which is expected to reach US$1.0 Billion by 2030 with a CAGR of a 8.4%. The Antihistamines segment is also set to grow at 7.9% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $385.7 Million in 2023, and China, forecasted to grow at an impressive 12.0% CAGR to reach $636.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AB Science, Boehringer Ingelheim, Ceva, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Key Questions Answered:

  • How is the Global Canine Atopic Dermatitis Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Canine Atopic Dermatitis Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Canine Atopic Dermatitis Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Select Competitors (Total 42 Featured):

  • AB Science
  • Boehringer Ingelheim
  • Ceva
  • Elanco
  • Elanco Animal Health
  • indred Biosciences Inc.
  • Kindred Biosciences
  • Novartis
  • Toray Industries
  • Virbac
  • Zoetis

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Canine Atopic Dermatitis - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Canine Atopic Dermatitis Globally Drives Demand for Effective Treatments
  • Advances in Veterinary Dermatology Enhance Understanding and Management of Canine Atopic Dermatitis
  • Development of Novel Therapeutics for Canine Atopic Dermatitis Based on Human Atopic Dermatitis Research
  • Increased Pet Ownership and Spending on Pet Healthcare Propel Market Growth for Canine Dermatitis Products
  • Growing Awareness Among Pet Owners About Canine Allergies and Their Management Necessitates Specialized Care
  • Impact of Environmental Changes on the Incidence and Severity of Canine Atopic Dermatitis
  • Expansion of Pet Insurance and Coverage for Dermatological Conditions Improves Access to Treatments
  • Adoption of Immunotherapy and Biological Drugs in Veterinary Medicine Opens New Treatment Avenues
  • Technological Advancements in Diagnostic Tools for Early Detection of Atopic Dermatitis in Dogs
  • Role of Diet and Nutrition in Managing Canine Atopic Dermatitis Promotes Specialized Pet Food Market
  • Increased Use of Telemedicine and Digital Tools for Remote Diagnosis and Monitoring of Canine Health
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 2: World Historic Review for Canine Atopic Dermatitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 3: World 16-Year Perspective for Canine Atopic Dermatitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Glucocorticoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 5: World Historic Review for Glucocorticoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 6: World 16-Year Perspective for Glucocorticoids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Antihistamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 8: World Historic Review for Antihistamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 9: World 16-Year Perspective for Antihistamines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 11: World Historic Review for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 12: World 16-Year Perspective for Immunosuppressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for MAbs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 14: World Historic Review for MAbs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 15: World 16-Year Perspective for MAbs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 17: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 18: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 20: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 21: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 22: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 23: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 24: World 16-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 25: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 26: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 27: World 16-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 28: World Canine Atopic Dermatitis Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 29: USA Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 30: USA Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 31: USA 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
  • Table 32: USA Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 33: USA Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 34: USA 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
CANADA
  • Table 35: Canada Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 36: Canada Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 37: Canada 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
  • Table 38: Canada Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 39: Canada Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 40: Canada 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
JAPAN
  • Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 41: Japan Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 42: Japan Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 43: Japan 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
  • Table 44: Japan Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 45: Japan Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 46: Japan 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
CHINA
  • Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 47: China Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 48: China Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 49: China 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
  • Table 50: China Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 51: China Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 52: China 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
EUROPE
  • Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 53: Europe Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 54: Europe Historic Review for Canine Atopic Dermatitis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 55: Europe 16-Year Perspective for Canine Atopic Dermatitis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 56: Europe Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 57: Europe Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 58: Europe 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
  • Table 59: Europe Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 60: Europe Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 61: Europe 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
FRANCE
  • Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 62: France Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 63: France Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 64: France 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
  • Table 65: France Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 66: France Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 67: France 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
GERMANY
  • Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 68: Germany Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 69: Germany Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 70: Germany 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
  • Table 71: Germany Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 72: Germany Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 73: Germany 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
ITALY
  • Table 74: Italy Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 75: Italy Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 76: Italy 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
  • Table 77: Italy Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 78: Italy Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 79: Italy 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 80: UK Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 81: UK Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 82: UK 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
  • Table 83: UK Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 84: UK Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 85: UK 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
SPAIN
  • Table 86: Spain Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 87: Spain Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 88: Spain 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
  • Table 89: Spain Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 90: Spain Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 91: Spain 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
RUSSIA
  • Table 92: Russia Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 93: Russia Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 94: Russia 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
  • Table 95: Russia Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 96: Russia Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 97: Russia 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 98: Rest of Europe Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 99: Rest of Europe Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 100: Rest of Europe 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
  • Table 101: Rest of Europe Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 102: Rest of Europe Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 103: Rest of Europe 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 105: Asia-Pacific Historic Review for Canine Atopic Dermatitis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 106: Asia-Pacific 16-Year Perspective for Canine Atopic Dermatitis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 108: Asia-Pacific Historic Review for Canine Atopic Dermatitis by Product - Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 109: Asia-Pacific 16-Year Perspective for Canine Atopic Dermatitis by Product - Percentage Breakdown of Value Sales for Glucocorticoids, Antihistamines, Immunosuppressants, MAbs and Other Products for the Years 2014, 2024 & 2030
  • Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 111: Asia-Pacific Historic Review for Canine Atopic Dermatitis by Mode of Administration - Oral, Injectable and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 112: Asia-Pacific 16-Year Perspective for Canine Atopic Dermatitis by Mode of Administration - Percentage Breakdown of Value Sales for Oral, Injectable and Topical for the Years 2014, 2024 & 2030
AUSTRALIA
  • Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Canine Atopic Dermatitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AB Science
  • Boehringer Ingelheim
  • Ceva
  • Elanco
  • Elanco Animal Health
  • indred Biosciences Inc.
  • Kindred Biosciences
  • Novartis
  • Toray Industries
  • Virbac
  • Zoetis

Table Information